Monopar Therapeutics (MNPR) Net Cash Flow (2017 - 2020)

Monopar Therapeutics' Net Cash Flow history spans 4 years, with the latest figure at -$1.2 million for Q4 2020.

  • For Q4 2020, Net Cash Flow fell 114.31% year-over-year to -$1.2 million; the TTM value through Dec 2020 reached $3.5 million, down 44.39%, while the annual FY2024 figure was $38.5 million, 4367.57% up from the prior year.
  • Net Cash Flow for Q4 2020 was -$1.2 million at Monopar Therapeutics, down from $5.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $8.7 million in Q4 2019 and bottomed at -$1.2 million in Q4 2020.
  • The 4-year median for Net Cash Flow is -$622037.5 (2019), against an average of $866983.8.
  • The largest annual shift saw Net Cash Flow crashed 219.21% in 2018 before it soared 1301.71% in 2019.
  • A 4-year view of Net Cash Flow shows it stood at -$806020.0 in 2017, then grew by 9.99% to -$725482.0 in 2018, then skyrocketed by 1301.71% to $8.7 million in 2019, then crashed by 114.31% to -$1.2 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Net Cash Flow are -$1.2 million (Q4 2020), $5.4 million (Q3 2020), and -$49070.0 (Q2 2020).